Safety and efficacy of transfemoral intrahepatic portosystemic shunt for portal hypertension: A single-center retrospective study

Table 1 Patient characteristics

Index	TFIPS, n = 19	TIPS, n = 21	t/χ2	P value
Gender, male/female	17/2	18/3	0.019	0.889
Age in yr, mean ± SD	46.3 ± 13	45.7 ± 12	0.942	0.349
Duration of follow-up in mo	20 (7-34)	22 (9-35)
Etiology as viral/other	15/4	16/5	0.213	0.725
Child-Pugh stage, n			0.043	0.979
Stage A	5	5
Stage B	13	15
Stage C	1	1
Child-Pugh score	7.31 ± 1.60	6.88 ± 1.90	0.77	0.446
MELD score	11.62 ± 3.22	10.87 ± 2.24	0.862	0.394
Gastrointestinal bleeding, yes/no	18/1	20/1	0.005	0.942
Refractory ascites, yes/no	1/18	1/20	0.005	0.942
Blood ammonia	33.01 ± 17.89	34.33 ± 13.15	0.268	0.790
Previous splenectomy and devascularization, yes/no	3/16	4/17	0.049	0.826
Previous sclerotherapy, yes/no	17/2	19/2	0.169	0.681

MELD: Model for end-stage liver disease; TFIPS: Transfemoral intrahepatic portosystemic shunt; TIPS: Transjugular intrahepatic portosystemic shunt.